Nevro Gains FDA Approval for Costa Rica Manufacturing Operations

Nevro has received U.S. Food and Drug Administration (FDA) approval for manufacturing operations in Costa Rica to produce its spinal cord stimulation systems for chronic pain, including the HFX product platform.
 
The new facility is located in Alajuela, Costa Rica’s Coyol Free Trade Zone and is Nevro’s first global manufacturing operation.
 
“We are pleased that the FDA has approved our new global manufacturing operations in Costa Rica,” D. Keith Grossman, chairman, CEO, and president of Nevro told the press. “As part of our growth plans moving forward, this manufacturing facility will support our pipeline of future products to ensure that we have the most efficient cost structure and flexible capacity, while maintaining the highest level of quality control as we scale.  Thank you to our excellent Costa Rica team for delivering this very meaningful milestone for Nevro.”
 
The company aims to begin shipping products by the end of October with gradual production ramp-up for the rest of the year and through 2023.
 
“This investment will allow us to continue to accomplish our mission to deliver comprehensive, life-changing solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment,” commented Christofer Christoforou, VP of technical operations of Nevro. “The capabilities and operations are fully scalable and will allow us to accommodate additional growth and expansion of our product platform.”
 
By the end of this year, Nevro will have invested about $21 million to support the facility’s growth initiatives. 100 employees are currently employed at the 41,000-square-foot facility.